GE INTRODUCES THE WORLD'S FIRST NON-INVASIVE HEMODYNAMIC
PATIENT MONITORING SYSTEM WITH CARDIODYNAMIC'S
ICG TECHNOLOGY
I heard in the CC that GE already has many of these sold, so it should boost the next Q Net Income, hopefully to a profitable level. Mark
GE Medical Systems Information Technologies, the global leader in
Patient Monitoring, introduced the world's first and only patient
monitoring system capable of non-invasively acquiring and displaying
hemodynamic (blood flow) information. This advancement will provide
clinicians with critical information about the mechanical performance
of a patient's heart without an invasive procedure, so they can
provide patients with a fast, confident assessment and diagnosis.
The new system unites GE's Solar® 8000 patient monitor and
CardioDynamics (Nasdaq: CDIC - news) innovative BioZ® Impedance
Cardiography (ICG) technology to provide first-of-its-kind monitoring
technology to hospitals worldwide. The U.S. Food and Drug
Administration recently granted clearance for GE's new BioZ® ICG
module, and the system is now commercially available.
"GE conducted a survey of 700 physicians and nurses around the
world," said Kevin King, vice president of Clinical Systems at GE
Medical Systems Information Technologies. "The majority told us that
non-invasive hemodynamic monitoring was their number one unmet need."
Before the advent of CardioDynamics' BioZ ICG technology,
clinicians had to subjectively treat patients without necessary
hemodynamic information or utilize an invasive, and costly procedure
called a Pulmonary Artery Catheter (PAC). The real-time information
provided by GE's Solar monitors with the ICG feature will allow
clinicians to more quickly access hemodynamic information
traditionally provided by a PAC, without the invasive procedure.
According to King, GE's exciting new offering is the result of a
12-month collaborative technology effort between GE and
CardioDynamics. The company expects to install approximately 2000 of
the new Solar monitoring systems with ICG capabilities worldwide by
the end of 2002.
Contact: Jennifer Christiansen, 414/362-2544,
jennifer.christiansen@med.ge.com |
